These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 19864390)

  • 1. Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice.
    Zhang W; Choi Y; Haynes LM; Harcourt JL; Anderson LJ; Jones LP; Tripp RA
    J Virol; 2010 Jan; 84(2):1148-57. PubMed ID: 19864390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibodies to the central conserved region of respiratory syncytial virus (RSV) G protein block RSV G protein CX3C-CX3CR1 binding and cross-neutralize RSV A and B strains.
    Choi Y; Mason CS; Jones LP; Crabtree J; Jorquera PA; Tripp RA
    Viral Immunol; 2012 Jun; 25(3):193-203. PubMed ID: 22551066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutating the CX3C Motif in the G Protein Should Make a Live Respiratory Syncytial Virus Vaccine Safer and More Effective.
    Boyoglu-Barnum S; Todd SO; Meng J; Barnum TR; Chirkova T; Haynes LM; Jadhao SJ; Tripp RA; Oomens AG; Moore ML; Anderson LJ
    J Virol; 2017 May; 91(10):. PubMed ID: 28275196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Respiratory Syncytial Virus (RSV) G Protein Vaccines With Central Conserved Domain Mutations Induce CX3C-CX3CR1 Blocking Antibodies.
    Bergeron HC; Murray J; Nuñez Castrejon AM; DuBois RM; Tripp RA
    Viruses; 2021 Feb; 13(2):. PubMed ID: 33672319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-G protein antibody responses to respiratory syncytial virus infection or vaccination are associated with inhibition of G protein CX3C-CX3CR1 binding and leukocyte chemotaxis.
    Harcourt JL; Karron RA; Tripp RA
    J Infect Dis; 2004 Dec; 190(11):1936-40. PubMed ID: 15529257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Respiratory syncytial virus G protein CX3C motif impairs human airway epithelial and immune cell responses.
    Chirkova T; Boyoglu-Barnum S; Gaston KA; Malik FM; Trau SP; Oomens AG; Anderson LJ
    J Virol; 2013 Dec; 87(24):13466-79. PubMed ID: 24089561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanoparticle vaccines encompassing the respiratory syncytial virus (RSV) G protein CX3C chemokine motif induce robust immunity protecting from challenge and disease.
    Jorquera PA; Choi Y; Oakley KE; Powell TJ; Boyd JG; Palath N; Haynes LM; Anderson LJ; Tripp RA
    PLoS One; 2013; 8(9):e74905. PubMed ID: 24040360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Alterations to the CX3C Motif and Secreted Form of Human Respiratory Syncytial Virus (RSV) G Protein on Immune Responses to a Parainfluenza Virus Vector Expressing the RSV G Protein.
    Liang B; Kabatova B; Kabat J; Dorward DW; Liu X; Surman S; Liu X; Moseman AP; Buchholz UJ; Collins PL; Munir S
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30651356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA vaccine encoding central conserved region of G protein induces Th1 predominant immune response and protection from RSV infection in mice.
    Hua Y; Jiao YY; Ma Y; Peng XL; Fu YH; Zheng YP; Hong T; He JS
    Immunol Lett; 2016 Nov; 179():95-101. PubMed ID: 27688078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P.
    Haynes LM; Jones LP; Barskey A; Anderson LJ; Tripp RA
    J Virol; 2003 Sep; 77(18):9831-44. PubMed ID: 12941892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology.
    Murawski MR; McGinnes LW; Finberg RW; Kurt-Jones EA; Massare MJ; Smith G; Heaton PM; Fraire AE; Morrison TG
    J Virol; 2010 Jan; 84(2):1110-23. PubMed ID: 19889768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CX3CR1 is an important surface molecule for respiratory syncytial virus infection in human airway epithelial cells.
    Chirkova T; Lin S; Oomens AGP; Gaston KA; Boyoglu-Barnum S; Meng J; Stobart CC; Cotton CU; Hartert TV; Moore ML; Ziady AG; Anderson LJ
    J Gen Virol; 2015 Sep; 96(9):2543-2556. PubMed ID: 26297201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decrease in formalin-inactivated respiratory syncytial virus (FI-RSV) enhanced disease with RSV G glycoprotein peptide immunization in BALB/c mice.
    Rey GU; Miao C; Caidi H; Trivedi SU; Harcourt JL; Tripp RA; Anderson LJ; Haynes LM
    PLoS One; 2013; 8(12):e83075. PubMed ID: 24376637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A unique combination adjuvant modulates immune responses preventing vaccine-enhanced pulmonary histopathology after a single dose vaccination with fusion protein and challenge with respiratory syncytial virus.
    Lee Y; Ko EJ; Kim KH; Lee YT; Hwang HS; Kwon YM; Graham BS; Kang SM
    Virology; 2019 Aug; 534():1-13. PubMed ID: 31163351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal Vaccination with a Respiratory-Syncytial-Virus-Based Virus-like Particle Displaying the G Protein Conserved Region Induces Severe Weight Loss and Pathology upon Challenge with Wildtype Respiratory Syncytial Virus.
    Terhüja M; Siddappa M; Lamichhane P; Meshram CD; Snider TA; Ritchey JW; Oomens AGP
    Viruses; 2024 May; 16(6):. PubMed ID: 38932136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
    Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric virus-like particles containing a conserved region of the G protein in combination with a single peptide of the M2 protein confer protection against respiratory syncytial virus infection.
    Qiao L; Zhang Y; Chai F; Tan Y; Huo C; Pan Z
    Antiviral Res; 2016 Jul; 131():131-40. PubMed ID: 27154395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the role of N-glycosylation sites in the respiratory syncytial virus fusion protein in virus replication, syncytium formation and antigenicity.
    Leemans A; Boeren M; Van der Gucht W; Martinet W; Caljon G; Maes L; Cos P; Delputte P
    Virus Res; 2019 Jun; 266():58-68. PubMed ID: 31004621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the respiratory syncytial virus G-directed neutralizing antibody response in the human airway epithelial cell model.
    Kishko M; Catalan J; Swanson K; DiNapoli J; Wei CJ; Delagrave S; Chivukula S; Zhang L
    Virology; 2020 Nov; 550():21-26. PubMed ID: 32866728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.
    Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM
    Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.